Ascendis Pharma

ASND

Equity

ISIN null / Valor 26912602

NASDAQ (2026-01-27)

USD 238.80+2.20%

Ascendis Pharma
UMushroom community rating:

4.50 2 votes No rating yet

NegativeNeutralPositive

About company

Ascendis Pharma, founded in 2007, is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing innovative therapies for rare endocrine diseases. The company is publicly traded on the Nasdaq since 2015 and has a global presence with employees dedicated to improving patients' lives. In 2018, Ascendis Pharma formed VISEN Pharmaceuticals to focus on endocrinology and granted exclusive rights to develop and commercialize its rare disease therapies in Greater China. Key products include TransCon hGH, TransCon PTH, and TransCon CNP.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

89.4%1Y

94.9%3Y

57.1%5Y

Performance

41.4%1Y

47.3%3Y

49.2%5Y

Volatility

14590 M

Market cap (USD)

278,835

Daily traded volume (Shares)

137.5 / 135.01

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.50

2 votes

Performance:

4.50

Innovation:

5.00

Society:

5.00

Nature:

4.50

Joaquim Silva

United Kingdom, 20 Oct 2025

N/A

Wiktor Włodarczyk

Switzerland, 13 Oct 2025

Company has a potential to grow over long term, they are an innovative company which discoveries and inventions will have strong impact on medical research

EQUITIES OF THE SAME SECTOR

Biotest AG